Dana-Farber Cancer Institute unveils groundbreaking blood test for multiple myeloma 🩸🔬✨
Read Full Article
#DanaFarber #CancerResearch #MultipleMyeloma #BloodTest #MedicalInnovation
Read Full Article
#DanaFarber #CancerResearch #MultipleMyeloma #BloodTest #MedicalInnovation
EurekAlert!
Dana-Farber Cancer Institute unveils groundbreaking blood test for multiple myeloma
Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. The new method, known as SWIFT-seq, utilizes single-cell sequencing to profile…
In a US trial, teclistamab wiped out cancer completely in 78% of high risk myeloma patients, against 0% on standard treatment, and cut two year progression to 8%.
Read Full Article
#MultipleMyeloma #CancerResearch #ClinicalTrial
Read Full Article
#MultipleMyeloma #CancerResearch #ClinicalTrial
Nature
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial
Nature Medicine - In the randomized phase 2 ImmunoPRISM trial, patients with high-risk smoldering multiple myeloma (MM) showed higher rates of complete clinical responses in response to treatment...